AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Cadrenal Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG019STRT39
0.96▼ 0.01 (-1.03%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
0.97
Day's Range
0.93 – 1.00
52-Week Range
0.82 – 14.21
Volume
38.1K
Avg Volume
170.9K
Share Statistics
Shares Outstanding
Employees
5
Exchange
XNAS
Listed
2023-01-20
Share count as of August 13, 2026

Cadrenal Therapeutics, Inc. Common Stock (CVKD) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Cadrenal Therapeutics, Inc. Common Stock (CVKD)
What is Cadrenal Therapeutics, Inc. Common Stock's Market Cap?
Cadrenal Therapeutics, Inc. Common Stock's Market Cap is $3.4M, based on as-reported figures from SEC (XBRL) filings.
What is Cadrenal Therapeutics, Inc. Common Stock's Net Income (TTM)?
Cadrenal Therapeutics, Inc. Common Stock's Net Income (TTM) is -$11.9M, based on as-reported figures from SEC (XBRL) filings.
What is Cadrenal Therapeutics, Inc. Common Stock's EBITDA?
Cadrenal Therapeutics, Inc. Common Stock's EBITDA is -$12.0M, based on as-reported figures from SEC (XBRL) filings.
What is Cadrenal Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Cadrenal Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -3.33, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CVKDAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
General and administrative expenses
Research and development expenses
Depreciation expense
Total operating expenses
Loss from operations
Other income
Interest and dividend income
Total other income
Net loss and comprehensive loss
Net loss per common share, basic (in Dollars per share)
Net loss per common share, diluted (in Dollars per share)